High-dose aminothiadiazole in advanced colorectal cancer - An Illinois Cancer Center phase II trial

Gershon Y. Locker; Lary Kilton; Janardan D. Khandekar; Thomas E. Lad; Richard H. Knop; Kathy Albain; Richard Blough; Suzanne French; Al B. Benson

doi:10.1007/BF00873044

High-dose aminothiadiazole in advanced colorectal cancer - An Illinois Cancer Center phase II trial

Gershon Y. Locker^*, Lary Kilton, Janardan D. Khandekar, Thomas E. Lad, Richard H. Knop, Kathy Albain, Richard Blough, Suzanne French, Al B. Benson

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Thirty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly IV aminothiadiazole (175 mg/m² escalated to 200 mg/m²) with concomitant allopurinol and non-steroidal anti-inflammatory agents (NSAID's). Toxicity was predominantly GI, cutaneous, and chest pain/dyspnea. Twenty-five percent of patients had grade 3 or 4 toxicity. There were no responses in 27 evaluable patients. Median survival was 12 months. Aminothiadiazole, at higher doses than used in previous reports, when given with NSAID's, had no significant activity against large bowel cancer.

Original language	English (US)
Pages (from-to)	299-301
Number of pages	3
Journal	Investigational New Drugs
Volume	12
Issue number	4
DOIs	https://doi.org/10.1007/BF00873044
State	Published - Dec 1994

Keywords

ATDA
aminothiadiazole
colorectal cancer
large bowel carcinoma
phase II trial

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF00873044

Cite this

@article{b6fa42de306c4f6fbe69fdb190c3aae8,

title = "High-dose aminothiadiazole in advanced colorectal cancer - An Illinois Cancer Center phase II trial",

abstract = "Thirty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly IV aminothiadiazole (175 mg/m2 escalated to 200 mg/m2) with concomitant allopurinol and non-steroidal anti-inflammatory agents (NSAID's). Toxicity was predominantly GI, cutaneous, and chest pain/dyspnea. Twenty-five percent of patients had grade 3 or 4 toxicity. There were no responses in 27 evaluable patients. Median survival was 12 months. Aminothiadiazole, at higher doses than used in previous reports, when given with NSAID's, had no significant activity against large bowel cancer.",

keywords = "ATDA, aminothiadiazole, colorectal cancer, large bowel carcinoma, phase II trial",

author = "Locker, {Gershon Y.} and Lary Kilton and Khandekar, {Janardan D.} and Lad, {Thomas E.} and Knop, {Richard H.} and Kathy Albain and Richard Blough and Suzanne French and Benson, {Al B.}",

year = "1994",

month = dec,

doi = "10.1007/BF00873044",

language = "English (US)",

volume = "12",

pages = "299--301",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "4",

}

TY - JOUR

T1 - High-dose aminothiadiazole in advanced colorectal cancer - An Illinois Cancer Center phase II trial

AU - Locker, Gershon Y.

AU - Kilton, Lary

AU - Khandekar, Janardan D.

AU - Lad, Thomas E.

AU - Knop, Richard H.

AU - Albain, Kathy

AU - Blough, Richard

AU - French, Suzanne

AU - Benson, Al B.

PY - 1994/12

Y1 - 1994/12

N2 - Thirty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly IV aminothiadiazole (175 mg/m2 escalated to 200 mg/m2) with concomitant allopurinol and non-steroidal anti-inflammatory agents (NSAID's). Toxicity was predominantly GI, cutaneous, and chest pain/dyspnea. Twenty-five percent of patients had grade 3 or 4 toxicity. There were no responses in 27 evaluable patients. Median survival was 12 months. Aminothiadiazole, at higher doses than used in previous reports, when given with NSAID's, had no significant activity against large bowel cancer.

AB - Thirty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly IV aminothiadiazole (175 mg/m2 escalated to 200 mg/m2) with concomitant allopurinol and non-steroidal anti-inflammatory agents (NSAID's). Toxicity was predominantly GI, cutaneous, and chest pain/dyspnea. Twenty-five percent of patients had grade 3 or 4 toxicity. There were no responses in 27 evaluable patients. Median survival was 12 months. Aminothiadiazole, at higher doses than used in previous reports, when given with NSAID's, had no significant activity against large bowel cancer.

KW - ATDA

KW - aminothiadiazole

KW - colorectal cancer

KW - large bowel carcinoma

KW - phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0028641647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028641647&partnerID=8YFLogxK

U2 - 10.1007/BF00873044

DO - 10.1007/BF00873044

M3 - Article

C2 - 7775130

AN - SCOPUS:0028641647

SN - 0167-6997

VL - 12

SP - 299

EP - 301

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 4

ER -

High-dose aminothiadiazole in advanced colorectal cancer - An Illinois Cancer Center phase II trial

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this